ProCE Banner Series

Community Practice Grand Rounds: Experts Explore the Latest Evidence and Guideline Updates in Chronic Lymphocytic Leukemia

Register now for this interactive, case-based workshop series to learn more about how to align current clinical practice with NCCN CLL/SLL guidelines and how to select and sequence treatments based patient characteristics and comorbidities while integrating patient preferences in the care of patients with CLL/SLL. After the meeting, download the associated slideset for use in your clinic.

Who Should Attend

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Topics

Management of CLL/SLL

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge, competence, and performance in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Target Audience
This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference

  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action

  • Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (eg, assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)

  • Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-25-003-L01-P

Type of activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/64a7123f4dc56.jpg

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

ILNA Coding

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Click here for a list of available ILNA points. Total ILNA points available: 1.0

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

 

Acknowledgement

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

This activity is supported by educational grants from AstraZeneca and Lilly. This activity is supported by an independent medical education grant from AbbVie.